Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype

Abstract Background The role of ivermectin in the treatment of COVID-19 is still under debate, yet the drug has been widely used in some parts of the world, as shown by impressive market data. The available body of evidence may have changed over the last months, as studies have been retracted and “standards of care” (SOC) used in control groups have changed with rapidly evolving knowledge on COVID-19. This review aims to summarize and critically appraise the evidence of randomized controlled trials (RCTs) of ivermectin, assessing clinical outcomes in COVID-19 patients. Methods RCTs evaluating the effects of ivermectin in adult patients with COVID-19 were searched through June 22, 2022, in four databases, L.OVE platform, clinical trial registries and pre-prints platforms. Primary endpoints included all-cause mortality and invasive ventilation requirement. Secondary endpoint was the occurrence of adverse events. Risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. Meta-analysis included only studies which compared ivermectin to placebo or SOC. Random-effects were used to pool the risk ratios (RRs) of individual trials. The quality of evidence was evaluated using GRADE. The protocol was register in PROSPERO (CRD42021257471). Results Twenty-five RCTs fulfilled inclusion criteria (n = 6310). Of those, 14 compared ivermectin with placebo, in night ivermectin associated with SOC was compared to SOC and two studies compared ivermectin to an active comparator. Most RCTs had some concerns or high risk of bias, mostly due to lack of concealment of the randomization sequence and allocation, lack of blinding and high number of missing cases. Ivermectin did not show an effect in reducing mortality (RR = 0.76; 95%CI: 0.52–1.11) or mechanical ventilation (RR = 0.74; 95%CI: 0.48–1.16). This effect was consistent when comparing ivermectin vs. placebo, and ivermectin associated with SOC vs. SOC, as well as in sensitivity analysis. Additionally, there was very low quality of evidence regarding adverse effects (RR = 1.07; 95%CI: 0.84–1.35). Conclusions The evidence suggests that ivermectin does not reduce mortality risk and the risk of mechanical ventilation requirement. Although we did not observe an increase in the risk of adverse effects, the evidence is very uncertain regarding this endpoint

Dicionário de ATS

2. ed

Artificial urinary sphincter for urinary incontinence after radical prostatectomy: a historical cohort from 2004 to 2015

ABSTRACT This study aimed to retrospectively evaluate a cohort of patients with prostate cancer and persistent urinary incontinence after radical prostatectomy. From January 2004 to December 2015, eighty-six individuals were identified to have received an AUS implant, provided by a private nonprofit HMO operating in Belo Horizonte, Brazil. On total, there were 91 AUS implants, with a median interval between radical prostatectomy and AUS implant of 3.6 years (IQR 1.9 to 5.5). The rate of AUS cumulative survival, after a median follow-up of 4.1 years (IQR 1.7-7.2 years), was 44% (n=40). The median survival of AUS implants was 2.9 years (IQR 0.5-7.9 years). Thirty-seven AUS implants (40.7%) resulted in grade III surgical complications. There were 5 deaths at 2.1, 4.7, 5.7, 5.7 and 6.5 years of follow-up, but none due to causes directly associated to the AUS implant. Persistent severe incontinence was documented in 14 (15.3%) additional patients. From the 51 AUS implants which resulted in grade III surgical complications or persistent severe incontinence, 24 (47.1%) underwent surgical revisions. Explantation of the sphincter or its components was observed in 6 cases (25.0%). Mechanical failure, described as fluid loss and/or inability to recycle the AUS device, was observed in 4 devices (16.7%). In conclusion, although AUS implants are recommended as the gold-standard treatment of severe urinary incontinence after prostatectomy, the observed high rates of malfunction and grade III adverse events are a matter of concern warranting further assessment on the safety and efficacy of these devices

La Voz de Asturias : diario de información: Año X Número 2797 - 1932 Abril 05

OBJETIVO: O artigo descreve as estratégias do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil) para a manutenção da adesão dos participantes ao longo do tempo e seu seguimento adequado. Isto é fundamental para garantir a validade interna de estudos longitudinais e identifi car, investigar e classifi car os desfechos incidentes de interesse. MÉTODOS: A metodologia de seguimento da coorte combina contatos telefônicos anuais com re-exames e entrevistas a cada três ou quatro anos. O objetivo é identifi car desfechos incidentes de natureza transitória, reversíveis ou não; desfechos fi nais, de natureza irreversível; bem como complicações relacionadas à evolução das doenças cardiovasculares e diabetes, principais doenças estudadas. RESULTADOS: As entrevistas telefônicas visam monitorar a saúde dos participantes e identifi car possíveis eventos ocorridos, como internações hospitalares, exames ou procedimentos especializados defi nidos previamente. O participante também é incentivado a comunicar a ocorrência de algum evento de saúde ao Centro de Pesquisa. A partir da identifi cação de um potencial evento, é iniciado um processo de investigação, que inclui acesso a prontuários médicos para verifi cação de datas e informações detalhadas sobre aquele evento. Os documentos obtidos são analisados sem identifi cação do paciente, profi ssional ou serviço de saúde e classifi cados por um comitê de especialistas médicos. A classifi cação de desfechos incidentes adotada baseia-se em critérios internacionais consagrados, garantindo comparabilidade e reduzindo o erro de classifi cação deles. Além dessas estratégias, a ocorrência de desfechos poderá ser investigada por meio do relacionamento de dados com bases secundárias do Ministério da Saúde, como as de mortalidade e internações. CONCLUSÕES: A correta identifi cação de desfechos permitirá estimar sua incidência na coorte e investigar o efeito das exposições estudadas no ELSABrasil em sua linha de base e nas ondas posteriores.OBJECTIVE: The article describes the strategies adopted by the Brazilian Longitudinal Study for Adult Health (ELSA-Brasil) for participation and retention of subjects. This is key to ensure internal validity of longitudinal studies, and to identify, investigate, and ascertain outcomes of interest. METHODS: The follow-up strategies include annual telephone contacts with new assessments and interviews every three to four years this approach aims to identify transient outcomes (reversible or not), permanent outcomes as well as complications related to the progression of major diseases – cardiovascular diseases and diabetes – to be studied. RESULTS: Telephone interviews are designed to monitor subjects’ health status and to identify potential health-related events such as hospital admissions, medical visits or pre-selected medical procedures. Subjects are also encouraged to report to the ELSA-Brasil team any new health-related events. When a potential event is identifi ed, a thorough investigation is carried out to collect relevant information about that event from medical records. All data are blinded and reviewed and analyzed by a medical expert committee. Incident outcome ascertainment follows well-established international criteria to ensure data comparability and avoid misclassifi cation. In addition to these strategies, the occurrence of health-related events is also investigated through linkage of secondary databases, such as national mortality and hospital admission databases. CONCLUSIONS: Accurate identification of outcomes will allow to estimating their incidence in the study cohort and to investigate the effect of the exposures studied in the ELSA-Brasil at baseline and at its subsequent waves